At a glance
ClinicalIndex Comparison RecordN/ACompleted· 40 enrolled
Drug / intervention
ABI-007drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MPACT Extension Study: Multicenter, Survival Data Collection in Subjects Previously Enrolled in Protocol CA046
In Brief
An observational study evaluating ABI-007 for Pancreatic Cancer. Completed, enrolled 40 participants across 39 sites in 9 countries.
Detailed Summary
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesAustralia, Austria, Canada, France, Germany, Italy, Spain, Ukraine, United States
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartJan 2014
Primary CompletionApr 2015
TodayJul 2026
First PostedDec 27, 2013
Enrollment StartJan 2, 2014
Primary CompletionApr 16, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 12.5 years ago
Interventions
ABI-007drug
No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)